( April 2, 2026, 1:01 PM EDT) -- CHICAGO — Eli Lilly & Co. urges the U.S. Supreme Court to review a Seventh Circuit U.S. Court of Appeals decision that affirmed a final judgment of $193 million for a qui tam relator who sued Lilly for reporting falsely deflated drug prices to the government in order to profit off of drug rebate programs, arguing in a petition for a writ of certiorari that the case “vividly illustrates the real-world problems with the . . . qui tam regime” under the False Claims Act (FCA)....